来那度胺-话题@MedSci

#来那度胺#

11篇内容 | 3007人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2236029, encodeId=a37c223602961, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=fd2b14453b9' target=_blank style='color:#2F92EE;'>#POEMS#</a>, objectTitle=北京协和医院225例POEMS综合征接受含来那度胺一线治疗长期预后良好, objectType=article, longId=850364, objectId=ea07850364c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241108/1731046030949_8538692.jpg, objectUrl=/article/show_article.do?id=ea07850364c7, replyNumber=0, likeNumber=21, createdTime=2024-11-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ea07850364c7, moduleTitle=北京协和医院225例POEMS综合征接受含来那度胺一线治疗长期预后良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea07850364c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2222300, encodeId=b3022222300fa, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=f33110964155' target=_blank style='color:#2F92EE;'>#骨髓增生异常肿瘤#</a>, objectTitle=【Leukemia】del(5q) MDS患者来那度胺治疗12个月后或可实现停药, objectType=article, longId=840385, objectId=e2988403856c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240802/1722585125228_8538692.png, objectUrl=/article/show_article.do?id=e2988403856c, replyNumber=0, likeNumber=80, createdTime=2024-08-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e2988403856c, moduleTitle=【Leukemia】del(5q) MDS患者来那度胺治疗12个月后或可实现停药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2988403856c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2222072, encodeId=2ef222220e2cb, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a> <a href='/topic/show?id=569f4453e38' target=_blank style='color:#2F92EE;'>#奥妥珠单抗#</a>, objectTitle=【EClinicalMedicine】奥妥珠单抗联合来那度胺治疗复发难治性惰性NHL, objectType=article, longId=840071, objectId=b4bc8400e1ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240730/1722330274156_8538692.jpg, objectUrl=/article/show_article.do?id=b4bc8400e1ad, replyNumber=0, likeNumber=73, createdTime=2024-08-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b4bc8400e1ad, moduleTitle=【EClinicalMedicine】奥妥珠单抗联合来那度胺治疗复发难治性惰性NHL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4bc8400e1ad)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2219091, encodeId=ba9b2219091a3, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a> <a href='/topic/show?id=ca679389279' target=_blank style='color:#2F92EE;'>#边缘区淋巴瘤#</a> <a href='/topic/show?id=736011e6628e' target=_blank style='color:#2F92EE;'>#MIL62#</a>, objectTitle=【EClinicalMedicine】CD20抗体MIL62联合来那度胺治疗R/R FL或MZL的1b/2期研究结果, objectType=article, longId=837988, objectId=5deb83e98896, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240607/1717772960834_5579292.jpg, objectUrl=/article/show_article.do?id=5deb83e98896, replyNumber=0, likeNumber=87, createdTime=2024-08-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5deb83e98896, moduleTitle=【EClinicalMedicine】CD20抗体MIL62联合来那度胺治疗R/R FL或MZL的1b/2期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5deb83e98896)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2218577, encodeId=344122185e77d, content=<a href='/topic/show?id=fab3101964cd' target=_blank style='color:#2F92EE;'>#骨髓增生异常综合征#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>, objectTitle=【柳叶刀血液学】低剂量来那度胺治疗非输血依赖低危del(5q) MDS的3期研究, objectType=article, longId=837699, objectId=372883e699ee, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240725/1721893810359_8538692.png, objectUrl=/article/show_article.do?id=372883e699ee, replyNumber=0, likeNumber=69, createdTime=2024-08-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=372883e699ee, moduleTitle=【柳叶刀血液学】低剂量来那度胺治疗非输血依赖低危del(5q) MDS的3期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=372883e699ee)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2218364, encodeId=537d221836475, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>, objectTitle=【Blood Adv】伊沙佐米、泊马度胺、地塞米松治疗首次复发的来那度胺难治性骨髓瘤的II期研究, objectType=article, longId=837444, objectId=a9fb83e4442b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240802/1722575535210_8538692.jpg, objectUrl=/article/show_article.do?id=a9fb83e4442b, replyNumber=0, likeNumber=89, createdTime=2024-08-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a9fb83e4442b, moduleTitle=【Blood Adv】伊沙佐米、泊马度胺、地塞米松治疗首次复发的来那度胺难治性骨髓瘤的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9fb83e4442b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2217185, encodeId=c24d221e18523, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> 多发性骨髓瘤 (MM) 是一种常见的血液系统恶性肿瘤，其特征是骨髓中浆细胞的异常增生，近年来，随着新疗法的出现，多发性骨髓瘤患者的生存期有所延长，然而，几乎所有多发性骨髓瘤患者最终都会经历复发和疾病进展，需要进一步的治疗，来那度胺是一种免疫调节剂，常用于多发性骨髓瘤的一线治疗，然而，许多患者在首次复发时对来那度胺产生耐药性，这给后续治疗带来了挑战，目前，对于耐药性是否与来那度胺剂量相关仍存在争议，该研究旨在评估对标准剂量来那度胺耐药和低剂量来那度胺耐药的多发性骨髓瘤患者在后续治疗中的预后，来那度胺耐药性是否与剂量相关。, objectTitle=来那度胺, objectType=topic, longId=61566, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301015/1697392777472_4754896.webp, objectUrl=null, replyNumber=0, likeNumber=38, createdTime=2024-07-28, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2217120, encodeId=bf77221e120b1, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, objectTitle=Blood Cancer J | 多发性骨髓瘤中不同剂量来那度胺耐药性的影响：一项回顾性研究, objectType=article, longId=836094, objectId=c4fa83609414, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240724/1721828252657_6145188.jpg, objectUrl=/article/show_article.do?id=c4fa83609414, replyNumber=0, likeNumber=68, createdTime=2024-07-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c4fa83609414, moduleTitle=Blood Cancer J | 多发性骨髓瘤中不同剂量来那度胺耐药性的影响：一项回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4fa83609414)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213417, encodeId=2f4e221341e61, content=<a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=c4a844521e5' target=_blank style='color:#2F92EE;'>#套细胞淋巴瘤#</a>, objectTitle=【Blood】BR±V诱导和利妥昔单抗±来那度胺维持治疗初治MCL的随机研究, objectType=article, longId=833001, objectId=35ee83300117, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720151052608_5579292.png, objectUrl=/article/show_article.do?id=35ee83300117, replyNumber=0, likeNumber=89, createdTime=2024-07-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=35ee83300117, moduleTitle=【Blood】BR±V诱导和利妥昔单抗±来那度胺维持治疗初治MCL的随机研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35ee83300117)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209282, encodeId=08472209282e1, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=901a1153803e' target=_blank style='color:#2F92EE;'>#Dara-KRd#</a>, objectTitle=【BCJ】24周期Dara-KRd不伴移植治疗新诊断多发性骨髓瘤的II期研究结果, objectType=article, longId=829410, objectId=ee6282941093, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240610/1718033892155_5579292.png, objectUrl=/article/show_article.do?id=ee6282941093, replyNumber=0, likeNumber=130, createdTime=2024-06-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ee6282941093, moduleTitle=【BCJ】24周期Dara-KRd不伴移植治疗新诊断多发性骨髓瘤的II期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee6282941093)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205418, encodeId=4817220541825, content=<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=1f931146049e' target=_blank style='color:#2F92EE;'>#侵袭性B细胞非霍奇金淋巴瘤#</a> <a href='/topic/show?id=86dc11460570' target=_blank style='color:#2F92EE;'>#阿可替尼#</a>, objectTitle=【Nat Commun】阿可替尼+来那度胺+利妥昔单抗治疗R/R侵袭性B-NHL的II期研究, objectType=article, longId=826396, objectId=6c2d826396a7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716030480304_5579292.png, objectUrl=/article/show_article.do?id=6c2d826396a7, replyNumber=0, likeNumber=0, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6c2d826396a7, moduleTitle=【Nat Commun】阿可替尼+来那度胺+利妥昔单抗治疗R/R侵袭性B-NHL的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c2d826396a7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2198437, encodeId=5077219843e8a, content=<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=f8ed113380c7' target=_blank style='color:#2F92EE;'>#阿卡替尼#</a> <a href='/topic/show?id=8c9810e7351f' target=_blank style='color:#2F92EE;'>#复发/难治性B细胞非霍奇金淋巴瘤#</a>, objectTitle=阿卡替尼与来那度胺和利妥昔单抗联合治疗复发/难治性侵袭性 B 细胞非霍奇金淋巴瘤：一项单臂 II 期试验, objectType=article, longId=818436, objectId=5fa781843627, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PAJM2K5.jpg, objectUrl=/article/show_article.do?id=5fa781843627, replyNumber=0, likeNumber=101, createdTime=2024-04-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=5fa781843627, moduleTitle=阿卡替尼与来那度胺和利妥昔单抗联合治疗复发/难治性侵袭性 B 细胞非霍奇金淋巴瘤：一项单臂 II 期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fa781843627)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2196313, encodeId=104b219631367, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a> <a href='/topic/show?id=674769813be' target=_blank style='color:#2F92EE;'>#甲氨蝶呤#</a> <a href='/topic/show?id=f7603e0370d' target=_blank style='color:#2F92EE;'>#原发性中枢神经系统淋巴瘤#</a>, objectTitle=来那度胺、利妥昔单抗和甲氨蝶呤联合对新诊断的原发性中枢神经系统淋巴瘤有效, objectType=article, longId=813024, objectId=ddbe813024e9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=ddbe813024e9, replyNumber=0, likeNumber=108, createdTime=2024-03-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=ddbe813024e9, moduleTitle=来那度胺、利妥昔单抗和甲氨蝶呤联合对新诊断的原发性中枢神经系统淋巴瘤有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddbe813024e9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194836, encodeId=e777219483694, content=<a href='/topic/show?id=ff1c3654ebf' target=_blank style='color:#2F92EE;'>#卡非佐米#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=816711259435' target=_blank style='color:#2F92EE;'>#原发性浆细胞白血病#</a>, objectTitle=Lancet Oncol | 以卡非佐米和来那度胺为基础的治疗方案治疗原发性浆细胞白血病：非随机、多中心、2期研究的最终分析, objectType=article, longId=817765, objectId=8b0081e76527, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240322/1711115554493_6145188.jpg, objectUrl=/article/show_article.do?id=8b0081e76527, replyNumber=0, likeNumber=103, createdTime=2024-03-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8b0081e76527, moduleTitle=Lancet Oncol | 以卡非佐米和来那度胺为基础的治疗方案治疗原发性浆细胞白血病：非随机、多中心、2期研究的最终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b0081e76527)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2170031, encodeId=5fd421e00317c, content=<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a> <a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a> <a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, objectTitle=来那度胺联合利妥昔单抗治疗老年体弱DLBCL：FIL_ReRi期II期研究, objectType=article, longId=799658, objectId=1a46e9965884, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=1a46e9965884, replyNumber=0, likeNumber=122, createdTime=2023-11-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1a46e9965884, moduleTitle=来那度胺联合利妥昔单抗治疗老年体弱DLBCL：FIL_ReRi期II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a46e9965884)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2163246, encodeId=c63c216324675, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>联合<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>治疗复发或难治性<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>显示疗效，它也可能与<a href='/topic/show?id=173c10e04660' target=_blank style='color:#2F92EE;'>#E-SHAP#</a>（依托泊苷、甲基强的松龙、阿糖胞苷、顺铂）方案发挥协同作用。, objectTitle=来那度胺联合R-ESHAP治疗复发或难治性弥漫性大B细胞淋巴瘤:GELTAMO的一项2期研究(NCT02340936), objectType=article, longId=794070, objectId=a5eae94070f0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=a5eae94070f0, replyNumber=0, likeNumber=108, createdTime=2023-10-17, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a5eae94070f0, moduleTitle=来那度胺联合R-ESHAP治疗复发或难治性弥漫性大B细胞淋巴瘤:GELTAMO的一项2期研究(NCT02340936), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5eae94070f0)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2117668, encodeId=cacb211e6689a, content=<a href='/topic/show?id=3ec02566625' target=_blank style='color:#2F92EE;'>#伊沙佐米#</a>联合<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>和<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>治疗复发或难治性<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870], objectType=guider, longId=22614, objectId=1d7071c00299e514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=1d7071c00299e514, replyNumber=2, likeNumber=137, createdTime=2023-03-05, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1d7071c00299e514, moduleTitle=2023 NICE 技术鉴定指导意见：伊沙佐米联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤[TA870], moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=1d7071c00299e514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2121879, encodeId=348421218e91e, content=此外与<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>或<a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a>相比，<a href='/topic/show?id=368d105e1469' target=_blank style='color:#2F92EE;'>#iberdomide#</a>在结合<a href='/topic/show?id=e75c44989f' target=_blank style='color:#2F92EE;'>#Cereblon#</a>中显示出更高的亲和力，可导致靶蛋白（包括转录因子 Ikaros 和Aiolos）强效降解，从而转化为更强效的抗<a href='/topic/show?id=793a101990ac' target=_blank style='color:#2F92EE;'>#骨髓瘤#</a>和免疫调节作用。, objectTitle=Lancet Haematol：Iberdomide治疗重度预处理多发性骨髓瘤结果，未来新治疗基石？, objectType=article, longId=743774, objectId=1037e4377463, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/5f4271881054417b8c087eee008824de.jpg, objectUrl=/article/show_article.do?id=1037e4377463, replyNumber=0, likeNumber=150, createdTime=2023-03-26, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1037e4377463, moduleTitle=Lancet Haematol：Iberdomide治疗重度预处理多发性骨髓瘤结果，未来新治疗基石？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1037e4377463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2113348, encodeId=8cc221133486a, content=<a href='/topic/show?id=37041503158' target=_blank style='color:#2F92EE;'>#R-CHOP方案#</a>是<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>（DLBCL）的标准一线治疗，但仍有约40%的患者复发/难治，因此很多学者都探索在R-CHOP的基础上加入其他药物（R-CHOP+X），希望进一步改善疗效。然而成功的路都是孤独的，目前仅POLARIX研究证实<a href='/topic/show?id=3ce21052613b' target=_blank style='color:#2F92EE;'>#维泊妥珠单抗#</a>（Polatuzumab）联合R-CHP方案优于R-CHOP，其他如<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>、<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>、<a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a>等均折戟沉沙。看来，真不容易！！伊布替尼只能找一些亚组人群，看是否可能有获益，这项研究是成功的。不知道是否有联合<a href='/topic/show?id=234613893a4' target=_blank style='color:#2F92EE;'>#PD-1#</a>治疗的，另外，未来还需要新的靶向药物，联合R-CHOP, objectTitle=Blood Adv：伊布替尼+R-CHOP可改善双表达初治DLBCL的EFS：PHOENIX研究亚组分析, objectType=article, longId=758647, objectId=966de586470e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/c7bf510bce68486aa92f3ac9c6b160df.jpg, objectUrl=/article/show_article.do?id=966de586470e, replyNumber=0, likeNumber=148, createdTime=2023-02-07, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=966de586470e, moduleTitle=Blood Adv：伊布替尼+R-CHOP可改善双表达初治DLBCL的EFS：PHOENIX研究亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=966de586470e)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1222743, encodeId=b9181222e43e6, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a>+<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>一线治疗不适移植的<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>的疗效可期！, objectTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, objectType=article, longId=218592, objectId=454b218592dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211015/1634282603340_2570354.jpg, objectUrl=/article/show_article.do?id=454b218592dd, replyNumber=0, likeNumber=147, createdTime=2022-05-27, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454b218592dd, moduleTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=454b218592dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

来那度胺

2020-05-29发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#来那度胺# #POEMS#

北京协和医院225例POEMS综合征接受含来那度胺一线治疗长期预后良好

2024-11-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#MDS# #来那度胺# #骨髓增生异常肿瘤#

【Leukemia】del(5q) MDS患者来那度胺治疗12个月后或可实现停药

2024-08-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#来那度胺# #NHL# #奥妥珠单抗#

【EClinicalMedicine】奥妥珠单抗联合来那度胺治疗复发难治性惰性NHL

2024-08-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#来那度胺# #滤泡性淋巴瘤# #边缘区淋巴瘤# #MIL62#

【EClinicalMedicine】CD20抗体MIL62联合来那度胺治疗R/R FL或MZL的1b/2期研究结果

2024-08-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#骨髓增生异常综合征# #来那度胺#

【柳叶刀血液学】低剂量来那度胺治疗非输血依赖低危del(5q) MDS的3期研究

2024-08-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #来那度胺# #地塞米松# #泊马度胺# #伊沙佐米#

【Blood Adv】伊沙佐米、泊马度胺、地塞米松治疗首次复发的来那度胺难治性骨髓瘤的II期研究

2024-08-03发表于上海

yangchou (审核中...)

前往app查看评论内容

全文收起 #来那度胺# 多发性骨髓瘤 (MM) 是一种常见的血液系统恶性肿瘤，其特征是骨髓中浆细胞的异常增生，近年来，随着新疗法的出现，多发性骨髓瘤患者的生存期有所延长，然而，几乎所有多发性骨髓瘤患者最终都会经历复发和疾病进展，需要进一步的治疗，来那度胺是一种免疫调节剂，常用于多发性骨髓瘤的一线治疗，然而，许多患者在首次复发时对来那度胺产生耐药性，这给后续治疗带来了挑战，目前，对于耐药性是否与来那度胺剂量相关仍存在争议，该研究旨在评估对标准剂量来那度胺耐药和低剂量来那度胺耐药的多发性骨髓瘤患者在后续治疗中的预后，来那度胺耐药性是否与剂量相关。

2024-07-28发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #来那度胺# #回顾性研究#

Blood Cancer J | 多发性骨髓瘤中不同剂量来那度胺耐药性的影响：一项回顾性研究

2024-07-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#硼替佐米# #来那度胺# #套细胞淋巴瘤#

【Blood】BR±V诱导和利妥昔单抗±来那度胺维持治疗初治MCL的随机研究